Terren Peizer

From Wikipedia, the free encyclopedia
Terren Scott Peizer
Born (1959-07-31) July 31, 1959 (age 62)
Beachwood, Ohio
Alma materWharton School of the University of Pennsylvania
OccupationFinancier
Websitewww.terrenpeizer.com

Terren Scott Peizer, is an investor and company executive. He is the CEO of Acuitas Group Holdings and Neurmedix.[1] He is also the CEO and chairman of Ontrak.[2] He has held senior executive positions within technology and biotech companies, at Goldman Sachs and First Boston,[1] and as a bond salesman at Drexel Burnham Lambert.[3][4]

Early life and education[]

Peizer's hometown is Beachwood, Ohio.[5] Peizer graduated from the Wharton School of the University of Pennsylvania.[1]

Career[]

In 1983, Peizer worked at Goldman Sachs[1] and later worked at First Boston as a salesman. Michael Milken hired Peizer as a bond salesman at Drexel Burnham Lambert in 1985.[6] He was the manager of David M. Solomon's account with Drexel[5] and given a 3.5 million dollar salary and a $500.000 loan to invest in the partnership.[7] Peizer worked directly under (and at the same desk as) Milken and admired him, sometimes pretending to be him on the phone, and calling him "Dad".[8] When investigations into Milken's illegal activities started, Peizer agreed to provide material evidence to prosecutors in exchange for immunity.[9]

In 1989 Peizer purchased the Omaha Racers, a minor league basketball team.[10] In 1991 he bought UTI Chemicals Inc. through his company Financial Group Holdings Inc.[11] and stepped down as its chairman in 1994.[12]

In 1993 he was elected Chairman at CMS Enhancements after acquiring a 36.8% share of the company.[13] From 1997 to 1999, Peizer was president of Hollis-Eden, a pharmaceutical company.[14][15] In 1999 Peizer raised money for Tera Computer Company, a manufacturer of supercomputers, which allowed them to later buy out Cray Research and became its chairman and a director.[16] He stepped back down as chairman in 2000 because the company was concerned that he would not obtain a security clearance from the United States Department of Defense by the end of 2000 to transfer Cray's classified business from Silicon Graphics, causing Cray Research to pay a penalty fee to Silicon Graphics.[17]

Peizer founded Hythiam Inc., a pharmaceutical company, in 2004.[18] The firm bought the rights to Juan Jose Legarda's addiction treatment pharmaceuticals.[19] 60 Minutes and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing Prometa to market.[20][21]

In 2018, Peizer became CEO and director of BioVie, a pharmaceutical company.[22]

References[]

  1. ^ a b c d "Catasys Inc (CATS.OQ)". Reuters. Retrieved 2020-11-25.[dead link]
  2. ^ Hackett, Mallory (2020-11-03). "Ontrak deepens its behavioral health platform with LifeDojo acquisition". MobiHealthNews. Retrieved 2020-11-25.
  3. ^ Labaton, Stephen (1988-12-10). "4th Drexel Employee in Immunity Bargain". The New York Times. ISSN 0362-4331. Retrieved 2020-11-25.
  4. ^ "Kohlberg, Kravis Official Tells of a Hidden Milken Stake". The New York Times.
  5. ^ a b Lee, Patrick (1994-07-31). "In the Shadow of the '80s : Yesterday's High Rollers Struggle in a New Era of Sobriety". Los Angeles Times. Retrieved 2020-11-26.
  6. ^ "No Sales, but Watch the Stock Soar". The New York Times.
  7. ^ Kornbluth, Jesse. Highly confident: The Crime and Punishment of Michael Milken. p. 213.
  8. ^ Griffin, Nancy; Masters, Kim (12 January 2016). Hit & Run: How Jon Peters and Peter Guber Took Sony for a Ride in Hollywood. ISBN 9781439128046.
  9. ^ "4th Drexel Employee in Immunity Bargain". The New York Times.
  10. ^ "Omaha CBA team sold to Los Angeles banker". The Lincoln Star. 7 September 1989. p. 18. Retrieved 11 August 2020.
  11. ^ Michaud, Anne (1991-04-10). "Drexel Figure Gains Control of UTI Chemicals". Los Angeles Times. Retrieved 2020-11-25.
  12. ^ "Jim Orefice has been appointed chairman..." Los Angeles Times. 1994-02-07. Retrieved 2020-11-26.
  13. ^ "CMS Enhancements Names New Top Management Team". LA Times.
  14. ^ "Market Place; No Sales, but Watch the Stock Soar". The New York Times.
  15. ^ "Small world, ain't it?". Forbes. 1999-09-05. Retrieved 2020-11-25.
  16. ^ "L.A. Financier Reemerges as Key Player in Cray Deal". Los Angeles Business Journal.
  17. ^ "Technology Briefs". Wall Street Journal. 2000-12-26. ISSN 0099-9660. Retrieved 2020-11-25.
  18. ^ Bartholomew, Dana (7 December 2018). "Catasys Thrives on Data Dives". Los Angeles Business Journal. Retrieved 12 August 2020.
  19. ^ Alpert, Bill. "Curb Your Cravings For This Stock". Barrons. Retrieved 2020-11-26.
  20. ^ "Prescription For Addiction". 60 Minutes. CBS News. December 9, 2007. Archived from the original on 2007-12-31. Retrieved 2008-08-22.
  21. ^ Ramshaw, Emily (January 20, 2008). "Texas' Prometa program for treating meth addicts draws skeptics". Dallas Morning News. Archived from the original on 2010-10-27.
  22. ^ Iral, Vince (2018-07-04). "BioVie sells stock, warrants to Acuitas, names CEO". S&P Global. Retrieved 2020-11-25.
Retrieved from ""